Market access // Prof. Lieven Annemans about Pharmaceutical pricing and risk sharing schemes

Risks related to the introduction of new medicines: to share or not to share?
One of the key challenges being faced today in pharmaceutical pricing, is the uncertainty of evidence generation: uncertainty about the target population, the effects of the treatment, the long term impact and so on. Risk sharing agreements can help to manage uncertainty whilst still getting optimal patient access. Lieven Annemans explains the different types of risk sharing agreements and how risk sharing agreements can play a very important role in achieving optimal patient access to the right medicines.

Lieven Annemans is a professor in health economics at Gent University and health economics expert at Vintura.

Want to know more about market access? Vintura is a strategic consultancy company focusing on life sciences and healthcare sectors with a team of over 25 highly skilled consultants. Our experience in international markets allows us to support clients across Europe and beyond. Go to https://www.vintura.com/en/life-scien... or get in touch with Bas Amesz.

Read more? Lieven Annemans wrote a book about health-economics for non-economists: https://nolledz.com/product/health-ec...